## *Amendments to the Specification*

Please replace paragraph [0017] with the following amended paragraph:

**[0017]** A fragment of the complete human HLA-A*0201 MHC class I α chain sequence (SEQ ID NO:1) has been described that folds independently into an MHC class I α3 domain and binds β2-microglobulin, Fayen, J. *et al. Mol. Immunol.* 32:267 (1995). In what follows any homologous MHC class I α chain fragment that is either (i) identical to this previously described MHC class I α3 domain sequence or (ii) has substitutions of less than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids which result in no more than a factor of 10 reduction in affinity for β2-microglobulin or (iii) extends further into the transmembrane and/or the α2 domain of the native α chain sequence and to which β2-microglobulin binds with an affinity that remains less than one tenth the binding affinity of β2-microglobulin for the intact MHC class I α chain or (iv) is shorter by any amount which is still compatible with no more than a factor of 10 reduction in affinity for β2-microglobulin will be referred to as an MHC class I α3 domain.

Please replace Table 1, on page 19, with the following amended Table 1:

Table 1 – Predicted C35 MHC Class I epitopes*

| HLA restriction element | Inclusive amino acids | Sequence |
|---|---|---|
| A*0201 | 9-17 | SVAPPPEEV (SEQ ID NO:7) |
| A*0201 | 10-17 | VAPPPEEV (SEQ ID NO:8) |
| A*0201 | 16-23 | EVEPGSGV (SEQ ID NO:9) |
| A*0201 | 16-25 | EVEPGSGVRI (SEQ ID NO:10) |
| A*0201 | 36-43 | EATYLELA (SEQ ID NO:11) |
| A*0201 | 37-45 | ATYLELASA (SEQ ID NO:12) |
| A*0201 | 37-46 | ATYLELASAV (SEQ ID NO:13) |
| A*0201 | 39-46 | YLELASAV (SEQ ID NO:14) |
| A*0201 | 44-53 | SAVKEQYPGI (SEQ ID NO:15) |
| A*0201 | 45-53 | AVKEQYPGI (SEQ ID NO:16) |
| A*0201 | 52-59 | GIEIESRL (SEQ ID NO:17) |

| HLA restriction element | Inclusive amino acids | Sequence |
|---|---|---|
| A*0201 | 54-62 | EIESRLGGT (SEQ ID NO:18) |
| A*0201 | 58-67 | RLGGTGAFEI (SEQ ID NO:19) |
| A*0201 | 61-69 | GTGAFEIEI (SEQ ID NO:20) |
| A*0201 | 66-73 | EIEINGQL (SEQ ID NO:21) |
| A*0201 | 66-74 | EIEINGQLV (SEQ ID NO:22) |
| A*0201 | 88-96 | DLIEAIRRA (SEQ ID NO:23) |
| A*0201 | 89-96 | LIEAIRRA (SEQ ID NO:24) |
| A*0201 | 92-101 | AIRRASNGET (SEQ ID NO:25) |
| A*0201 | 95-102 | RASNGETL (SEQ ID NO:26) |
| A*0201 | 104-113 | KITNSRPPCV (SEQ ID NO:27) |
| A*0201 | 105-113 | ITNSRPPCV (SEQ ID NO:28) |
| A*0201 | 105-114 | ITNSRPPCVI (SEQ ID NO:29) |
| A*3101 | 16-24 | EVEPGSGVR (SEQ ID NO:30) |
| B*3501 | 30-38 | EPCGFEATY (SEQ ID NO:31) |
| A*30101 supermotif | 96-104 | ASNGETLEK (SEQ ID NO:32) |
| *predicted using rules found at the SYFPEITHI website ~~(wysiwyg://35/http://134.2.96.221/scripts/hlaserver.dll/EpPredict.htm)~~ and are based on the book "MHC Ligands and Peptide Motifs" by Rammensee, H.G., Bachmann, J. and S. Stevanovic. Chapman & Hall, New York, 1997. | | |